Dupilumab,Dupixent,REGN668,Inhibitor reseptor interleukin,Biologi Imunologi,Antibodi Monoklonal,CAS No.1190264-60-8
Nama Dagang : Dupixent
Target : N/A
Tipe Molekuler : Antibodi Monoklonal
Penjualan pada 2025 (Juta USD) : 1340 (Tiga kuartal pertama)
Semua informasi produk terperinci akan tunduk pada COA akhir yang diterbitkan.
Jika Anda memerlukan dokumentasi lebih mendalam untuk item ini, silakan hubungi kami.
Bevacizumab,Avastin,VEGF,Anti-VEGF monoklonal antibodi,Anti-VEGF monoklonal antibodi,Humanized IgG1 antibodi,Oncology biologic / Antiangiogenic therapy,CAS No. 216974-75-3
Trade Name : Avastin Target : VEGF Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.
Vedolizumab ,Entyvio ,MLN0002 ,Biologik anti-integrin ,Antibodi monoklonal IgG1 yang dihumanisasi ,Terapi IBD / Biologik kolitis ulserativa / Biologik penyakit Crohn ,No. CAS 943609-66-3
Trade Name : Entyvio Target : N/A Molecular Type : N/A Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.
Imiglucerase,Cerezyme,rGCR,GBA (β- glucocerebrosid ase),Glycoprotein (Ini adalah protein yang mengandung 497 asam amino, diproduksi dengan menggunakan teknologi DNA rekombinan), CAS No. 154248-97-2
Trade Name : Cerezyme® Target : GBA (β- glucocerebrosid ase) Molecular Type : Glycoprotein (This is a protein containing 497 amino acids, produced using recombinant DNA technology) Sales in 2025 (Millions of USD) : 1105(estimate) All detailed product information shall be subject to the issued final ...
Luspatercept-aamt
Trade Name : Reblozyl Target : Transforming growth factor-β (TGF- β)superfamily ligands Molecular Type : Recombinant Fusion Protein Sales in 2025 (Millions of USD) : 2000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for ...
